Metabolomics, metabolic flux analysis and cancer pharmacology

• Published in: Pharmacology & therapeutics (Oxford) Vol. 224; p. 107827
• Main Authors: Liang, Lingfan, Sun, Fei, Wang, Hongbo, Hu, Zeping
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01.08.2021
• Subjects: cancer; drug discovery; Humans; metabolic flux; Metabolic Flux Analysis; Metabolomics; Neoplasms - drug therapy; pharmacology; cancer; drug discovery; metabolomics; metabolic flux; pharmacology
• ISSN: 0163-7258; 1879-016X; 1879-016X
• DOI: 10.1016/j.pharmthera.2021.107827

Metabolic reprogramming is a hallmark of cancer and increasing evidence suggests that reprogrammed cell metabolism supports tumor initiation, progression, metastasis and drug resistance. Understanding metabolic dysregulation may provide therapeutic targets and facilitate drug research and development for cancer therapy. Metabolomics enables the high-throughput characterization of a large scale of small molecule metabolites in cells, tissues and biofluids, while metabolic flux analysis (MFA) tracks dynamic metabolic activities using stable isotope tracer methods. Recent advances in metabolomics and MFA technologies make them powerful tools for metabolic profiling and characterizing metabolic activities in health and disease, especially in cancer research. In this review, we introduce recent advances in metabolomics and MFA analytical technologies, and provide the first comprehensive summary of the most commonly used isotope tracing methods. In addition, we highlight how metabolomics and MFA are applied in cancer pharmacology studies particularly for discovering targetable metabolic vulnerabilities, understanding the mechanisms of drug action and drug resistance, exploring potential strategies with dietary intervention, identifying cancer biomarkers, as well as enabling precision treatment with pharmacometabolomics.